How should recurrent epistaxis be evaluated and managed in a healthy 31‑year‑old Asian woman without obvious traumatic cause?

Management of Recurrent Epistaxis in a 31-Year-Old Asian Female

Apply firm, continuous pressure to the soft lower third of the nose for 10–15 minutes without checking for cessation, then add topical oxymetazoline spray and continue compression for another 5–10 minutes; this first-line approach resolves 65–75% of cases and should be taught for home management of future episodes. 1

Immediate Assessment Priorities

Document critical risk factors that increase bleeding frequency or severity:

• Personal or family history of bleeding disorders (von Willebrand disease, hemophilia, easy bruising, prolonged bleeding from minor cuts) 1, 2
• All anticoagulant or antiplatelet medications (aspirin, NSAIDs, warfarin, direct oral anticoagulants) 1, 2
• Intranasal drug use—including topical corticosteroids (which increase epistaxis risk 2.7-fold), nasal decongestant overuse, cocaine, or other inhaled substances 1, 2
• Environmental exposures: dry climate, low humidity, nasal oxygen, CPAP use 1, 3
• Digital trauma (nose picking) and vigorous nose blowing 1

Obtain a baseline blood pressure because approximately one-third of epistaxis patients have undiagnosed hypertension, but do not acutely lower blood pressure during active bleeding—excessive reduction can precipitate renal, cerebral, or coronary ischemia. 1, 3

Diagnostic Evaluation

Perform anterior rhinoscopy after removing blood clots by suction or gentle nose blowing to identify the bleeding source, most commonly the Kiesselbach plexus on the anterior nasal septum. 1, 2, 3

Proceed to nasal endoscopy if:

• Anterior rhinoscopy fails to identify the source 1, 3
• Bleeding recurs despite prior treatment 1, 2
• Bleeding is difficult to control 1, 3
• Unilateral epistaxis with nasal obstruction, facial pain, or visual changes (to exclude masses, foreign bodies, or malignancy) 3

Nasal endoscopy localizes the bleeding site in 87–93% of cases. 1, 3

Screen for hereditary hemorrhagic telangiectasia (HHT) if:

• Recurrent bilateral nosebleeds 1, 2
• Family history of recurrent nosebleeds 1, 2
• Visible nasal or oral mucosal telangiectasias on examination 1, 2

Definitive Treatment When Bleeding Source Is Identified

Anesthetize the identified bleeding site with topical lidocaine or tetracaine, then cauterize only the active bleeding point. 1, 3 Electrocautery is superior to chemical cauterization, with recurrence rates of 14.5% versus 35.1%, respectively. 1 Silver nitrate cauterization achieves an 80% initial success rate. 4

Critical safety warning: Avoid bilateral simultaneous septal cautery—this markedly increases the risk of septal perforation. 1, 3

Management When Bleeding Persists

Initiate nasal packing only when:

• Bleeding continues after 15–30 minutes of proper compression combined with topical vasoconstrictors 1
• Life-threatening hemorrhage is present 1
• A posterior bleeding source is suspected 1

Use only resorbable/absorbable packing materials (Nasopore, Surgicel, Floseal) to minimize trauma during removal, especially in patients with bleeding risk factors. 1, 2 Non-resorbable packing carries a 50% recurrence rate compared to <10% for surgical interventions. 1

Prevention of Recurrence—The Cornerstone of Long-Term Management

Aggressive nasal mucosal moisturization is essential:

• Apply petroleum jelly or nasal saline gel to the anterior nasal mucosa 2–3 times daily 1, 2
• Use saline nasal sprays frequently throughout the day 1
• Place a bedside humidifier in dry environments 1
• Avoid digital trauma and vigorous nose blowing for at least 7–10 days after any intervention 1

Medication Management Considerations

If the patient is on intranasal corticosteroids, discontinue them—these medications increase epistaxis risk with a relative risk of 2.74 (range 1.88–4.00). 2

Do not discontinue systemic anticoagulant or antiplatelet therapy for recurrent epistaxis unless bleeding is life-threatening; withholding anticoagulation increases thrombotic risk, which carries higher morbidity and mortality than the epistaxis itself. 1, 2 Prioritize first-line local measures (compression, vasoconstrictors, cautery, packing) before contemplating medication withdrawal. 1

Indications for Otolaryngology Referral

Refer to an otolaryngology specialist when:

• Bleeding persists despite appropriate cauterization and moisturization 1, 3
• Three or more episodes of recurrent epistaxis despite correct local treatment and preventive measures 1, 2
• Persistent or recurrent bleeding after failure of compression and packing—evaluate candidacy for endoscopic sphenopalatine artery ligation (97% success rate) or endovascular embolization (80% success rate) 1, 2
• HHT is suspected (refer to an HHT Center of Excellence for comprehensive multidisciplinary management) 1

Follow-Up and Documentation

Document outcomes within 30 days after any invasive treatment (cauterization, packing, surgical ligation, or embolization) to monitor for complications and recurrent bleeding. 1, 2 Adequate follow-up allows assessment for underlying conditions (primary bleeding disorders, hematologic malignancies, intranasal tumors, or vascular malformations) when treatments are ineffective or bleeding recurs. 5, 1

Common Pitfalls to Avoid

• Premature release of nasal compression is the most common cause of treatment failure—patients must maintain full 10–15 minutes of continuous pressure without checking. 1
• Overlooking HHT screening in patients with recurrent bilateral epistaxis or relevant family history. 1, 2
• Using non-resorbable packing in patients with bleeding risk factors or those who may require repeat packing. 1, 2
• Delaying endoscopic evaluation after multiple treatment failures—this can miss underlying pathology such as tumors. 1, 3
• Bilateral simultaneous septal cautery—this dramatically increases septal perforation risk. 1, 3